

Immune Design Corp

COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 18-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drugs..... 9

[Return to Table of Contents](#)

Immune Design Corp

COMPANY OVERVIEW

| | |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Company Name | Immune Design Corp |
| Parent Company Name | Immune Design Corp |
| Website | http://www.immunedesign.com/ |
| Country | US |
| Number of Drugs in Active Development | 9 |
| Number of Inactive Drugs | 1 |
| Number of Patents as Owner | 11 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 13 |
| Key Indications | Cancer, HSV-2 infection, Allergy, Influenza virus infection, Merkel cell carcinoma, Solid tumor, Vaccination, Viral infection, Bacterial infection, Fungal infection, Parasitic infection |
| Key Target-based Actions | TLR-4 agonist, T-cell surface glycoprotein CD8 stimulator, Carbonic anhydrase-IX stimulator, Glutamate carboxypeptidase II stimulator, HIV GAG protein stimulator, Hemagglutinin stimulator, Homeobox protein Nkx 3.1 stimulator, Prostate specific antigen stimulator, Prostatic acid phosphatase stimulator, Rev protein stimulator, TLR agonist, Viral envelope glycoprotein |
| Key Technologies | Biological therapeutic, Parenteral formulation unspecified, Systemic formulation unspecified, Virus recombinant, Gene transfer system viral, Drug combination, Intramuscular formulation, Intratumoral formulation, Antigen, Peptide, Vector expression |

COMPANY PROFILE

SUMMARY

Immune Design, founded in 2008, aims to develop prophylactic and therapeutic vaccines for infectious diseases, cancer, allergy and autoimmune disorders. The company has identified improved adjuvants and novel technologies targeting and controlling dendritic cells.

COMPANY LOCATION

The company is headquartered in Seattle, WA.

By October 2013, the company had expanded operations to include a San Francisco office with plans to further expand in the Bay Area.

LICENSING AGREEMENTS

In November 2008, the Immune Design Corp was granted a license to the Infectious Disease Research Institute (IDRI)'s Glycopyranosyl Lipid Adjuvant (GLA) technology, for combination with undisclosed therapeutic vaccine products in a number of indications. IDRI would retain worldwide exclusive rights to develop the technology for products against certain indications, including infectious disease, in the developing world, and would retain rights to develop the technology non-commercially for provision to not-for-profit organizations. Immune Design concurrently established its Global Access Plan, to provide better access to GLA-formulated products for diseases in the developing world.

FINANCIAL

In October 2013, the company raised \$49 million in a series C financing which included an upfront investment of \$32.5 million, with an additional investment of \$16.5 million.

In July 2010, Immune Design secured \$32 million in series B financing.

In June 2008, Immune Design raised \$18 million in series A financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|---------------------|--------|----------|-------|
| Neoplasm | 5 | 0 | 5 |
| Infectious disease | 2 | 1 | 3 |
| Prophylaxis | 1 | 1 | 2 |
| Respiratory disease | 1 | 1 | 2 |
| Immune disorder | 1 | 0 | 1 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 2 Clinical | 1 |
| Phase 1 Clinical | 3 |
| Discovery | 5 |
| No Development Reported | 1 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|----------------------------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 2 | 0 | 0 | 0 | 2 |
| Drug - Development/Commercialization License | 4 | 0 | 0 | 0 | 4 |
| Drug - Development Services | 0 | 0 | 5 | 0 | 5 |
| Technology - Delivery/Formulation | 1 | 0 | 1 | 0 | 2 |

CLINICAL TRIALS

[Return to Table of Contents](#)



Trials by Condition Studied

| Condition Studied | Ongoing | All |
|---------------------------|---------|-----|
| Neoplasm | 2 | 2 |
| Genitourinary disease | 1 | 1 |
| Endocrine disease | 1 | 1 |
| Respiratory disease | 1 | 1 |
| Gynecology and obstetrics | 1 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 1 | 2 | 3 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------------|----------|----------------|-------|
| Immune disorder | 4 | 0 | 4 |
| Neoplasm | 7 | 0 | 7 |
| Respiratory disease | 3 | 0 | 3 |
| Infectious disease | 11 | 0 | 11 |
| Inflammatory disease | 1 | 0 | 1 |
| Otorhinolaryngological disease | 1 | 0 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

therapeutic vaccine (GLA adjuvanted, pandemic influenza), Immune Design/Medicago

| | |
|-----------------------------|----------------------------------------------------------------------------------|
| Drug Name | therapeutic vaccine (GLA adjuvanted, pandemic influenza), Immune Design/Medicago |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Medicago Inc, Immune Design Corp |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Influenza virus infection |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Antiviral, Therapeutic vaccine |
| Technologies | Systemic formulation unspecified, Biological therapeutic |
| Last Change Date | 13-Nov-2013 |

glucopyranosyl lipid A adjuvant, Immune Design Corp

| | |
|-----------------------------|--------------------------------------------------------------|
| Drug Name | glucopyranosyl lipid A adjuvant, Immune Design Corp |
| Key Synonyms | |
| Originator Company | Infectious Disease Research Institute |
| Active Companies | Immune Design Corp |
| Inactive Companies | Infectious Disease Research Institute |
| Highest Status | Phase 1 Clinical |
| Active Indications | Vaccination |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Immunostimulant, Adjuvant |
| Technologies | Systemic formulation unspecified, Small molecule therapeutic |
| Last Change Date | 20-Jun-2013 |

[Return to Table of Contents](#)



G-305

| | |
|-----------------------------|---------------------------------------------------|
| Drug Name | G-305 |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Cancer |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Anticancer, Therapeutic vaccine |
| Technologies | Intramuscular formulation, Biological therapeutic |
| Last Change Date | 31-Dec-2013 |

ID-G100

| | |
|-----------------------------|--------------------------------------------------|
| Drug Name | ID-G100 |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Merkel cell carcinoma |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Therapeutic vaccine, Anticancer |
| Technologies | Intratumoral formulation, Biological therapeutic |
| Last Change Date | 28-Jan-2014 |

[Return to Table of Contents](#)



LV-305

| | |
|-----------------------------|-------------------------------------------------------------------------------|
| Drug Name | LV-305 |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | T-cell surface glycoprotein CD8 stimulator |
| Other Actions | Anticancer, Therapeutic vaccine, Retrovirus based gene therapy |
| Technologies | Virus recombinant, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 02-Nov-2013 |

IDC-G103

| | |
|-----------------------------|------------------------------------------------------------|
| Drug Name | IDC-G103 |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | HSV-2 infection |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Antiviral, Therapeutic vaccine |
| Technologies | Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 31-Jul-2013 |

[Return to Table of Contents](#)

therapeutic vaccine (GLA adjuvanted, allergy), Sanofi/Immune Design

| | |
|-----------------------------|---------------------------------------------------------------------|
| Drug Name | therapeutic vaccine (GLA adjuvanted, allergy), Sanofi/Immune Design |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp, Sanofi |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Allergy |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Therapeutic vaccine, Immunomodulator |
| Technologies | Systemic formulation unspecified, Biological therapeutic |
| Last Change Date | 31-Jul-2013 |

checkpoint inhibitors (LV-305 +/-GLA, cancer), Immune Design

| | |
|-----------------------------|----------------------------------------------------------------------------------------|
| Drug Name | checkpoint inhibitors (LV-305 +/-GLA, cancer), Immune Design |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | TLR-4 agonist |
| Other Actions | Immunostimulant, Retrovirus based gene therapy, Anticancer, Therapeutic vaccine |
| Technologies | Biological therapeutic, Parenteral formulation unspecified, Gene transfer system viral |
| Last Change Date | 30-Oct-2013 |

[Return to Table of Contents](#)

LV-305 + G-305

| | |
|-----------------------------|-------------------------------------------------------------------------------------------------|
| Drug Name | LV-305 + G-305 |
| Key Synonyms | |
| Originator Company | Immune Design Corp |
| Active Companies | Immune Design Corp |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Solid tumor |
| Target-based Actions | T-cell surface glycoprotein CD8 stimulator, TLR-4 agonist |
| Other Actions | Anticancer, Retrovirus based gene therapy, Therapeutic vaccine |
| Technologies | Drug combination, Virus recombinant, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 02-Nov-2013 |

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

